XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.48

+0.7%

Nov 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	2/24/2004 8:27:56 PM
From: Robert K.	Read Replies (4) of 17367

FYI>Serono is responsible for developing and commercializing Raptiva™ worldwide outside of the United States and Japan. During 2003, Serono submitted regulatory applications in key markets for the use of Raptiva™ in moderate-to-severe plaque psoriasis and currently expects to commence its launch program for this innovative therapy in the second half of 2004. Costs associated with the launch of Raptiva™ are projected to be between $30m and $50m in 2004.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next